|
|
Taiwan Academic Institutional Repository >
Browse by Author
|
"braiteh f"
Showing items 1-7 of 7 (1 Page(s) Totally)
1
View [10|25|50] records per page
| 臺大學術典藏 |
2021-01-05T00:56:27Z |
Long-term effects of crizotinib in ALK-positive tumors (excluding NSCLC): A phase 1b open-label study
|
Braiteh F.; Zhang L.; Orlov S.; Gambacorti-Passerini C.; Huang H.; Esaki T.; Horibe K.; Ahn J.-S.; Beck J.T.; Edenfield W.J.; Shi Y.; Taylor M.; Tamura K.; Van Tine B.A.; SHANG-JU WU; Paolini J.; Selaru P.; Kim T.M. |
| 國家衛生研究院 |
2017-11 |
Subgroup analysis by prior non-liposomal irinotecan therapy in NAPOLI-1: A phase 3 study of nal-IRI65-fluorouracil/leucovorin in patients with metastatic pancreatic ductal adenocarcinoma previously treated with gemcitabine-based therapy
|
Blanc, JF;Hubner, R;Li, CP;Wang-Gillam, A;Bodoky, G;Dean, A;Shan, YS;Jameson, G;Mercade, TM;Lee, KH;Cunningham, D;Chiu, CF;Schwartsmann, G;Braiteh, F;von Hoff, D;Chen, LT;Mamlouk, K;de Jong, F;Siveke, J |
| 國家衛生研究院 |
2016-10 |
Final results of NAPOLI-1: A phase 3 study of nal-IRI (MM-398) +/- 5-fluorouracil and leucovorin (5-FU/LV) vs 5-FU/LV in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine-based therapy
|
Chen, LT;Wang-Gillam, A;Li, CP;Bodoky, G;Dean, A;Shan, YS;Jameson, GS;Macarulla, T;Lee, KH;Cunningham, D;Blanc, JF;Hubner, R;Chiu, CF;Schwartsmann, G;Braiteh, F;Belanger, B;Bayever, E;de Jong, F;von Hoff, DD;Siveke, JT |
| 國家衛生研究院 |
2016-10 |
Time course of selected treatment emergent adverse events (TEAEs) in NAPOLI-1: A phase 3 study of nal-IRI (MM-398) +/- 5-fluorouracil and leucovorin (5-FU/LV) vs 5-FU/LV in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine-based ther
|
Hubner, RA;Chen, LT;Siveke, JT;Li, CP;Bodoky, G;Dean, A;Shan, YS;Jameson, GS;Macarulla, T;Lee, KH;Cunningham, D;Blanc, JF;Chiu, CF;Schwartsmann, G;Braiteh, F;Mamlouk, K;Belanger, B;de Jong, F;von Hoff, DD;Wang-Gillam, A |
| 國家衛生研究院 |
2016-02 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): A global, randomised, open-label, phase 3 trial
|
Wang-Gillam, A;Li, CP;Bodoky, G;Dean, A;Shan, YS;Jameson, G;Macarulla, T;Lee, KH;Cunningham, D;Blanc, JF;Hubner, RA;Chiu, CF;Schwartsmann, G;Siveke, JT;Braiteh, F;Moyo, V;Belanger, B;Dhindsa, N;Bayever, E;Von Hoff, DD;Chen, LT;the NAPOLI-1 Study Group. |
| 國家衛生研究院 |
2016-02 |
Expanded analyses of NAPOLI-1: Phase 3 study of nal-IRI (MM-398), with or without 5-fluorouracil (5FU) and leucovorin (LV), versus 5-fluorouracil and leucovorin (5FU/LV), in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine-based therapy
|
Siveke, JT;Chen, LT;Von Hoff, DD;Li, CP;Wang-Gillam, A;Bodoky, G;Dean, A;Shan, YS;Jameson, G;Macarulla, T;Lee, KH;Cunningham, D;Blanc, JF;Hubner, RA;Chiu, CF;Schwartsmann, G;Braiteh, F;Moyo, V;Belanger, B;Bayever, E |
| 國立成功大學 |
2016 |
Expanded analyses of NAPOLI-1: Phase 3 study of nal-IRI (MM-398), with or without 5-fluorouracil (5FU) and leucovorin (LV), versus 5-fluorouracil and leucovorin (5FU/LV), in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine-based therapy
|
Siveke, Jens T.;Chen, Li-Tzong;Von Hoff, Daniel D;Li, Chung-Pin;Wang-Gillam, Andrew;Bodoky, Gyorgy;Dean, Andrew;Shan, Yan-Shen;Jameson, Gayel S;Macarulla, T.;Lee, K-H;Cunningham, D.;Blanc, J-F;Hubner, R. A.;Chiu, C-F;Schwartsmann, G.;Braiteh, F.;Moyo, V.;Belanger, B.;Bayever, E. |
Showing items 1-7 of 7 (1 Page(s) Totally)
1
View [10|25|50] records per page
|
